Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health Lyme Testing Coverage & Coding | Open…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Lyme Disease Testing Coverage Criteria

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, indications, limitations, and acceptable testing methodologies for laboratory diagnosis of Lyme disease for Oscar Health members.

    Policy Summary
    PayerOscar Health
    PolicyLyme Disease Testing Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionConfirm member benefit coverage and authorization rules prior to ordering serologic two-tier (STTT) or FDA-cleared MTTT testing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Primary recommended serologic algorithms
    EM/asymptomaticTesting discouraged for
    LimitedPCR utility
    89kReported cases (2023)
    8

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Procedure codes listed
    2026-06-16Governance approved

    Coverage Criteria for Lyme Disease Testing

    Medically necessary indications for serologic testing

    Covered when ANY of the following clinical scenarios apply and testing follows a two-tier serologic algorithm (STTT) or an FDA-cleared MTTT:

    Indications meeting criteria: a) Early signs/symptoms of untreated Lyme disease with known tick or environmental exposure; b) Later signs/symptoms of untreated Lyme disease (may lack known tick exposure); c) Acute myocarditis or pericarditis of unknown cause; d) Meningitis, encephalitis, or myelitis; e) Painful radiculoneuritis; f) Mononeuropathy multiplex including confluent mononeuropathy multiplex; g) Acute cranial neuropathy.

    Serologic testing must use a sensitive EIA/IFA first-step followed by a western immunoblot confirmatory test or an FDA-cleared second EIA (MTTT).

    Repeat testing timing

    Repeat testing:

    Repeat serology: When initial serologic testing is negative but clinical suspicion persists, repeat serologic testing is medically necessary no sooner than 4 weeks after the previous test (NICE: 4–6 weeks; AAP: convalescent sample 2–3 weeks if indicated).>= 4 weeks

    Perform repeat testing per two-tier algorithm (EIA/IFA first; if positive/equivocal, perform confirmatory immunoblot or FDA-cleared second EIA).

    Not medically necessary / Excluded indications

    Not covered (testing DOES NOT MEET CRITERIA) in the following situations:

    Not covered indications: a) Individuals with erythema migrans rash; b) Asymptomatic screening; c) Individuals presenting solely with ALS, relapsing-remitting multiple sclerosis, Parkinson's disease, dementia/cognitive decline or new-onset seizures, or psychiatric illness without additional signs/symptoms of Lyme disease; d) Detection of Borrelia burgdorferi by nucleic acid identification techniques (direct or amplified probe) for routine diagnosis; e) Repeat serologic testing for individuals who previously tested positive; f) All other testing for Borrelia burgdorferi not described in covered methods (including proprietary or nonstandard assays lacking validation); g) Testing of the removed tick for diagnosis of Lyme disease.

    These exclusions reflect lack of benefit, high false-positive risk, or absence of validation in published literature.

    Appropriate and Inappropriate Testing (Guideline-driven)

    Coverage aligned with major guidelines — testing appropriate when clinical and epidemiologic context supports suspicion of Lyme disease; otherwise not recommended.

    CDC two-step serology: Perform an initial EIA or IFA; if the first-step is negative, no further testing of the specimen is recommended; if the first-step is positive or equivocal, perform a confirmatory immunoblot (or an FDA-cleared EIA as second-tier alternative).

    Results are considered positive only if both steps are positive.

    Clinical scenarios supporting testing: Testing is appropriate for patients with epidemiologically plausible exposure and compatible clinical manifestations (for example: meningitis, painful radiculoneuritis, mononeuropathy multiplex, acute cranial neuropathies, or acute myocarditis/pericarditis) but patients with clear erythema migrans should be diagnosed clinically without laboratory testing.

    Recommendations based on IDSA/AAN/ACR, AAP, CDC, and NICE guidance.

    Testing in suspected neuroborreliosis: Use serum antibody testing rather than PCR or culture for CSF or serum; if CSF testing is performed, obtain simultaneous CSF and serum for a CSF:serum antibody index using validated methodology and avoid CSF serology without the index.

    Proprietary and other nonstandard Lyme disease assays are considered unsupported for routine diagnostic use unless they align with accepted, validated methodologies. Examples called out in the policy include proprietary immunoblots and laboratory-developed assays that have limited independent validation, as well as nonstandard specimen types such as urine-based assays. The AAP and other authorities note that several commercially available tests lack broad validation and therefore are not appropriate as substitutes for the recommended serologic algorithms. When reporting or billing for proprietary or LDT assays, include the test name and performing laboratory per documentation requirements.

    Certain tests have been specifically identified as invalid or too nonspecific for diagnosis and therefore do not meet criteria. These include urine tests for Borrelia burgdorferi, the CD57 assay, novel culture techniques, and antibody panels that deviate from the standardized two-tier testing approach. The policy references AAP guidance stating these assays are not FDA-cleared and are not appropriate diagnostic tests because they can produce false-positive or otherwise uninterpretable results.

    None explicitly stated in these chunks.

    Serologic testing is not medically necessary for patients with a classic erythema migrans rash because this presentation should be diagnosed clinically without laboratory testing. The policy follows guideline recommendations that clinicians treat typical EM without reliance on serology. In addition, serology is not indicated for isolated neurologic or psychiatric complaints in the absence of other objective signs or epidemiologic exposure consistent with Lyme disease.

    Routine testing of asymptomatic individuals after a tick bite is discouraged and considered not medically necessary. Likewise, routine screening for nonspecific neurologic, psychiatric, or chronic conditions (for example ALS, MS, Parkinson’s disease, dementia, new-onset seizures, or nonspecific MRI white-matter changes) is not recommended and does not meet criteria unless other clinical or epidemiologic evidence supports testing.

    No explicit 'not medically necessary' statements are specified in these specific code-list chunks.

    Coding and Procedure Codes

    Applicable CPT/HCPCS and Proprietary Test Codesmixed
    86617Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot).
    86618Antibody; Borrelia burgdorferi (Lyme disease).
    87475Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, direct probe technique.
    87476Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, amplified probe technique.
    0041UBorrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM (Proprietary test: Lyme ImmunoBlot IgM, IGeneX Inc).
    0042UBorrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG (Proprietary test: Lyme ImmunoBlots IgG, IGeneX Inc).
    0580UBorrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, IgG (Proprietary test: iDartTM Lyme IgG ImmunoBlot Kit, ID-FISH Technology, Inc).
    0615UBorrelia burgdorferi (Lyme disease), antibody detection of 26 recombinant protein groups, by immunoassay, IgM (Test Name: iDart ™ Lyme IgM ImmunoBlot Kit, ID-FISH Technology, Inc).
    Applicable CPT/HCPCS/PLA CodesmixedCovered
    86617Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot).
    86618Antibody; Borrelia burgdorferi (Lyme disease).
    87475Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, direct probe technique.
    87476Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, amplified probe technique.
    0041UBorrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM (Proprietary test: Lyme ImmunoBlot IgM; Lab/Manufacturer: IGeneX Inc).
    0042UBorrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG (Proprietary test: Lyme ImmunoBlots IgG; Lab/Manufacturer: IGeneX Inc).
    0580UBorrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, IgG (Proprietary test: iDartTM Lyme IgG ImmunoBlot Kit; Lab/Manufacturer: ID-FISH Technology, Inc).
    0615UBorrelia burgdorferi (Lyme disease), antibody detection of 26 recombinant protein groups, by immunoassay, IgM (Test Name: iDart ™ Lyme IgM ImmunoBlot Kit; Laboratory: ID-FISH Technology, Inc).

    Provider Actions, Documentation, and Billing Guidance

    Prior Authorization

    Authorization note — confirm coverage before ordering

    Coverage for serologic two-tier testing (STTT) or an FDA-cleared modified two-tier testing (MTTT) meets criteria when clinical indications align with the policy; providers should confirm member benefit coverage and any authorization requirements prior to ordering testing.

    Billing Rule

    Listed procedure codes for Lyme testing

    Use the procedure and proprietary test codes listed in the policy when ordering or billing Lyme disease diagnostic testing.

    • 86617, 86618, 87475, 87476
    • 0041U, 0042U, 0580U, 0615U

    Background and Epidemiology

    Lyme disease in North America is caused primarily by Borrelia burgdorferi and is transmitted by infected Ixodes ticks. Early localized infection commonly presents with erythema migrans and non-specific viral-type symptoms; without treatment, infection can disseminate to involve the nervous system, heart, or joints. Serologic testing detects the host antibody response and is most sensitive in later stages; direct detection methods such as PCR have limited sensitivity in blood and are used selectively (for example, PCR of synovial fluid in suspected Lyme arthritis). Because antibody development may take weeks, serology is less sensitive in very early disease, and clinical judgment (including diagnosis of EM) should guide management.

    Definitions and Abbreviations

    EM (erythema migrans)
    TermEM (erythema migrans)
    DefinitionCharacteristic painless, often 'bulls-eye' rash at the tick-bite site; clinical diagnosis can be made without laboratory testing.
    Testing implicationSerologic testing is not recommended for patients with erythema migrans because the lesion appears prior to development of a diagnostic antibody response.
    STTT (standard two-tier testing)
    TermSTTT (standard two-tier testing)
    DefinitionA screening EIA or IFA followed by a confirmatory immunoblot (western blot) when the first-tier is positive or equivocal.

    Revision History and Governance

    2026-10-01publication_effectiveLatest

    Policy effective date published for Lyme Disease Testing.

    2026-06-16governance_approval

    Original documentation created and governance-approved for the Lyme Disease Testing policy.

    Policy Summary
    PayerOscar Health
    PolicyLyme Disease Testing Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionConfirm member benefit coverage and authorization rules prior to ordering serologic two-tier (STTT) or FDA-cleared MTTT testing.
    SourceLink
    On This Page
    Coverage Criteria for Lyme Disease TestingCoding and Procedure CodesProvider Actions, Documentation, and Billing GuidanceBackground and EpidemiologyDefinitions and AbbreviationsRevision History and Governance

    Strong recommendation in IDSA/AAN/ACR guidance.

    When not to test routinely: Do not routinely test asymptomatic patients after a tick bite; avoid testing for nonspecific neurologic, psychiatric, or chronic disorders (e.g., ALS, MS, Parkinson's, dementia, psychiatric illness) in the absence of other clinical or epidemiologic support.

    Multiple guideline recommendations cite high false-positive risk and low utility.

    Use of PCR and other direct detection: PCR on blood has limited yield and is not routinely recommended; PCR of synovial fluid can be informative for Lyme arthritis; molecular testing may detect B. burgdorferi in early disease and can identify some cases missed by serology, but direct detection methods are not a substitute for guideline-recommended serology in most settings.

    Guidance and evidence note variable sensitivity of molecular methods (AAP, IDSA statements).

    Prior Authorization

    Codes referenced for authorization checks

    When checking prior authorization or adjudicating claims, verify services are billed with the policy-listed CPT/HCPCS/PLA codes; these are the codes referenced throughout the policy for authorization and coverage review.

    • 86617, 86618, 87475, 87476, 0041U, 0042U, 0580U, 0615U
    Step Therapy

    Preferred testing algorithm (STTT or FDA‑cleared MTTT)

    The policy accepts a two-step serologic algorithm (screening EIA/IFA followed by immunoblot) or an FDA-cleared MTTT (an EIA followed by a second FDA-cleared EIA) as the approved testing pathway for serologic diagnosis of Lyme disease.

    • STTT: screening EIA/IFA then confirmatory western immunoblot
    • MTTT: first EIA then FDA-cleared second EIA as alternative to immunoblot
    Step Therapy

    CDC two-step testing requirement

    Follow CDC guidance: perform an initial EIA or IFA and only perform the second-step immunoblot if the first-step result is positive or indeterminate; if the first-step is negative, no further testing of that specimen is recommended.

    • First step: EIA or, rarely, IFA
    • If first step negative — do not perform further testing on that specimen
    • If first step positive or equivocal — perform immunoblot (or FDA-cleared alternative)
    Note
    Documentation Required

    Required clinical documentation to justify testing

    Providers must submit documentation that supports epidemiologic exposure, clinical signs/symptoms consistent with Lyme disease, and timing (e.g., early versus later disease) to justify serologic testing under the policy.

    • History of travel to or residence in an endemic area or known tick/environmental exposure
    • Signs/symptoms matching covered clinical scenarios (e.g., meningitis, radiculoneuritis, acute cranial neuropathy, myocarditis/pericarditis)
    • Timing of symptom onset relative to exposure and prior testing
    Documentation Required

    Specimen and documentation for suspected neuroborreliosis

    For suspected Lyme neuroborreliosis, obtain simultaneous CSF and serum samples and document that a CSF:serum antibody index will be determined by a laboratory using validated methodology; avoid CSF serology without the antibody index.

    • Collect CSF and serum at the same time for CSF:serum antibody index
    • Specify that the laboratory will use validated methods to determine the index
    Documentation Required

    LDT validation and performing laboratory identification

    Laboratory-developed tests (LDTs) for Lyme disease are CLIA-regulated as high-complexity tests; laboratories must validate and perform these LDTs in-house and the performing lab/test name should be included when submitting claims for proprietary or LDT assays.

    • LDTs are regulated under CLIA as high-complexity tests
    • LDTs are not necessarily FDA-cleared; labs must validate them and identify the performing lab on reports/claims
    Denial Risk

    Denial triggers and non-covered indications

    Claims may be denied or recouped if coding/billing guidelines or reimbursement policies are not followed; serologic testing is not covered for erythema migrans, asymptomatic screening, testing the tick, repeat serology after a prior positive, or other non‑described methods.

    • Serologic testing not covered for individuals with erythema migrans
    • Not covered for asymptomatic screening or testing the tick
    • Repeat serology after prior positive is not covered
    Denial Risk

    Adhere to two-step testing — do not confirm after negative first step

    If the first-step EIA/IFA is negative, do not order confirmatory immunoblot or further testing on that specimen — doing so may trigger denial as the CDC and policy advise no further testing when first-step is negative.

    • Negative first-step EIA/IFA → specimen considered seronegative; no further testing indicated
    • If first-step is equivocal or positive → proceed to second-step confirmatory testing
    Denial Risk

    Coding-based denial risk — bill with listed codes

    Use only the policy-listed CPT/HCPCS/PLA codes when billing Lyme disease laboratory testing; services billed outside these described codes may be denied or paid incorrectly.

    • Bill using listed codes: 86617, 86618, 87475, 87476, 0041U, 0042U, 0580U, 0615U
    • Claims submitted with other codes for these services may be subject to coding-based denial or incorrect payment
    Guidance
    If first-step EIA/IFA is negative, no further testing of the specimen is recommended per CDC/AAP guidance.
    MTTT (modified two-tier testing)
    TermMTTT (modified two-tier testing)
    DefinitionAn algorithm that replaces the second-tier western blot with a second EIA (or other FDA-cleared EIA-based confirmatory test).
    Regulatory noteCertain MTTT assays have been cleared by the FDA as acceptable second-tier alternatives to immunoblot when cleared for this purpose.
    Standard two-tiered testing (STTT)
    NameStandard two-tiered testing (STTT)
    AlgorithmInitial EIA or IFA screening; if negative, report as seronegative and do not perform further testing; if positive or equivocal, perform a confirmatory immunoblot (western blot).
    InterpretationResults are considered positive only if both the EIA/IFA and the immunoblot are positive.
    Modified two-tiered testing (MTTT)
    NameModified two-tiered testing (MTTT)
    AlgorithmAlternative two-step approach using a sensitive first-tier EIA followed by a different EIA (or FDA-cleared EIA) as the second-tier instead of an immunoblot.
    PerformanceMTTT has been reported to improve sensitivity for early B. burgdorferi infection compared with STTT while maintaining comparable specificity in studies cited in the policy.
    Laboratory-developed test (LDT)
    TermLaboratory-developed test (LDT)
    DefinitionA test developed and performed in-house by a laboratory; regulated under CLIA as a high-complexity test and not necessarily FDA-cleared or -approved.
    Regulatory implicationAs LDTs, these assays must be validated and are regulated by CMS under CLIA '88; FDA clearance is not required for clinical use but LDTs are not FDA-approved/cleared.